Data Integrity: US FDA Guidance Seeks To Head Off Bioavailability/Bioequivalence Study Problems

 
• By Sue Sutter
Drawing bullseye
A new guidance takes aim at the data integrity problems that have plagued industry in recent years. • Source: Shutterstock

More from Generics

More from Biosimilars & Generics